OB fusion protein compositions and methods

• US 20050163799A1
• Filed: 02/08/2005
• Published: 07/28/2005
• Est. Priority Date: 11/22/1995
• Status: Active Grant

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: Hecht, Randy Ira, Pelleymounter, Mary Ann, Toombs, Christopher Francis, Mann, Michael B.
• Granted Patent: US 7,112,659 B2
• Time in Patent Office: Days
• US Class Current: 424/192.100
• CPC Class Codes: A61K 38/2264 Obesity-gene products, e.g. leptin
• CPC Class Codes: C07K 14/5759 Products of obesity genes, e.g. leptin, obese (OB), tub, fat
• CPC Class Codes: C07K 19/00 Hybrid peptides , i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.

Claims

1. An isolated human leptin fusion protein comprising SEQ ID NO:

9, SEQ ID NO;

12, SEQ ID NO;

15, or SEQ ID NO;

18.

2. The fusion protein of claim 1 for use in increasing lean tissue mass.

3. The fusion protein of claim 1 for use in decreasing the dose of insulin required for the treatment of diabetes.

4. The fusion protein of claim 1 for use in regulating bone resorption.

5. The fusion protein of claim 1 for use in controlling serum glucose levels.

6. The fusion protein of claim 1 for use in increasing insulin sensitivity.

7. The fusion protein of claim 6, wherein the protein is administered to a human in need thereof.

8. The fusion protein of claim 7, wherein the human has diabetes.

9. The fusion protein of claim 7, wherein the protein is administered chronically in a therapeutically effective amount.